Substance / Medication

Sotrovimab

SNOMED 1162689008 UMLS C5433947

Overview

Active Ingredient

sotrovimab

RxNorm CUI

2550731

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Coronavirus infection

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19

NCT05305651Phase 4Completed217 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data.

Russo Antonio, Grimaldi Pierantonio, Pisaturo Mariantonietta et al. · Front Immunol · 2024

PMID: 38352882Meta-AnalysisFull text (PMC)

Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis.

Amani Bahman, Amani Behnam · Immun Inflamm Dis · 2024

PMID: 38652021Meta-AnalysisFull text (PMC)

Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials.

da Silva Amorim Ana Flávia, Sobalvarro Joselin Valeska Martinez, Torres Larissa Helena et al. · Naunyn Schmiedebergs Arch Pharmacol · 2024

PMID: 39031183Meta-Analysis

Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis.

Amani Behnam, Amani Bahman · Expert Rev Anti Infect Ther · 2024

PMID: 38457124Meta-Analysis

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.

Drysdale Myriam, Gibbons Daniel C, Singh Moushmi et al. · Infection · 2024

PMID: 37776474Meta-AnalysisFull text (PMC)

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review.

Drysdale Myriam, Berktas Mehmet, Gibbons Daniel C et al. · Infection · 2024

PMID: 38602623Meta-AnalysisFull text (PMC)

Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis.

Farhadian Negin, Farhadian Maryam, Zamanian Mohammad Hossein et al. · Immunopharmacol Immunotoxicol · 2023

PMID: 36537311Meta-Analysis

Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis.

Amani Bahman, Amani Behnam · Rev Med Virol · 2022

PMID: 36226323Meta-AnalysisFull text (PMC)

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis.

Ao Guangyu, Li Toni, Wang Yushu et al. · J Infect · 2022

PMID: 35461909Meta-AnalysisFull text (PMC)

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

[object Object] · Lancet Infect Dis · 2026

PMID: 40886716RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Sotrovimab (substance)
SNOMED CT: 1162689008
UMLS CUI: C5433947
RxNorm CUI: 2550731

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.